Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ilanit Burnstein"'
Autor:
Elizabeth Klinke, Wolf Mueller, Franz Fogt, Mats Sanden, Tina Bocker Edmonston, Yael Spector, Monica Huszar, Eti Meiri, Ulrike Lass, Karin Ashkenazi, Meora Feinmesser, Ilanit Burnstein, Shai Rosenwald, Iris Barshack, Nir Dromi, Eran Goren, Ranit Aharonov, Ayelet Chajut, Margot Werner, Merav Zepeniuk, Orit Zion
Publikováno v:
The Oncologist. 17:801-812
Background. Cancers of unknown primary origin (CUP) constitute 3%–5% (50,000 to 70,000 cases) of all newly diagnosed cancers per year in the United States. Including cancers of uncertain primary origin, the total number increases to 12%–15% (180,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09a29fb88930895688cc8aca2630112b
https://doi.org/10.1634/theoncologist.2011-0466
https://doi.org/10.1634/theoncologist.2011-0466
Autor:
Nir Dromi, Ranit Aharonov, Iris Barshack, Sima Benjamin, Irit Krivitsky, Ilanit Burnstein, Laurie Horowitz, Yajue Huang, Craig Thurm, J. Steve Hou, Michal Kushnir, Marluce Bibbo, Shlomit Gilad, Meora Feinmesser, Gila Lithwick-Yanai, Brianna St. Cyr, Hadas Gibori, Mats Sanden, Tina Bocker Edmonston
Publikováno v:
The Journal of molecular diagnostics : JMD. 14(5)
For patients with primary lung cancer, accurate determination of the tumor type significantly influences treatment decisions. However, techniques and methods for lung cancer typing lack standardization. In particular, owing to limited tumor sample am
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6409b3f8e3ae915d139141cdf41b60a0
https://pubmed.ncbi.nlm.nih.gov/22749746
https://pubmed.ncbi.nlm.nih.gov/22749746
Autor:
Meora Feinmesser, Monica Huszar, Tina Bocker Edmonston, B. St. Cyr, Eti Meiri, Wolf Mueller, Yael Spector, H. Shomin, Franz Fogt, Ilanit Burnstein, Nir Dromi, Eran Goren, Ranit Aharonov, Shai Rosenwald, Iris Barshack, Lahav Cohen
Publikováno v:
Journal of Clinical Oncology. 29:10575-10575
10575 Background: Cancer of unknown primary (CUP) constitutes 3%-5% of all newly diagnosed cancer cases. It presents a major diagnostic challenge as knowing the tumor tissue of origin (ToO) of the ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dca6c49e9510e2961c26293f3b424979
https://doi.org/10.1200/jco.2011.29.15_suppl.10575
https://doi.org/10.1200/jco.2011.29.15_suppl.10575